Lower drug prices can improve innovation
An often made claim is that high drug prices are necessary for innovation. We qualify this claim: drug prices can be too high, namely when the price exceeds the value of the drug to society. Such prices lead to excessive investment in some projects at the expense of other valuable research projects. We propose a benchmark for identifying these cases in practice and we discuss how competition law can be applied in this area.
Documents
We do our utmost to make our documents accessible.
However, this is unfortunately not always possible.
If you are unable to read a document on our website using a screen reader or if you are unable to discern the colors of charts,
please send us an email.
We will contact you within a week.
And we will try to send you an accessible version within 4 weeks.